$MXCT SEC Filings

Filed On	Filing
15 Oct 2026	SCHEDULE 13D
14 Oct 2026	8-K: Results of Operations and Financial Condition MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
13 Aug 2026	10-Q
12 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
04 Aug 2026	SCHEDULE 13D
29 Jul 2026	SCHEDULE 13G/A
22 Jun 2026	Form 4: Johnston John Joseph, Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
22 Jun 2026	Form 4: Hemrajani Rekha, Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
22 Jun 2026	Form 4: Erck Stanley C, Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
22 Jun 2026	Form 4: Douglas Richard, Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
22 Jun 2026	Form 4: Collins Cynthia, Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
22 Jun 2026	Form 4: Brooke William W, Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
22 Jun 2026	Form 4: Balthrop Patrick J, Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
22 Jun 2026	Form 4: Al-Wakeel Yasir B., Director Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy)
17 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
16 Jun 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
14 May 2026	SCHEDULE 13D
13 May 2026	10-Q
12 May 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
29 Apr 2026	ARS

Comments